Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Respir Res. 2011 Aug 15;12(1):108. doi: 10.1186/1465-9921-12-108.
Human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) attenuate hyperoxic neonatal lung injury primarily through anti-inflammatory effects. We hypothesized that intratracheal transplantation of human UCB-derived MSCs could attenuate Escherichia coli (E. coli)-induced acute lung injury (ALI) in mice by suppressing the inflammatory response.
Eight-week-old male ICR mice were randomized to control or ALI groups. ALI was induced by intratracheal E. coli instillation. Three-hours after E. coli instillation, MSCs, fibroblasts or phosphate-buffered saline were intratracheally administered randomly and survival was analyzed for 7 days post-injury. Lung histology including injury scores, myeloperoxidase (MPO) activity, and protein levels of interleukin (IL)-1α, IL-1β, IL-6, tumor necrosis factor (TNF)-α, and macrophage inflammatory protein (MIP)-2 as well as the wet-dry lung ratio and bacterial counts from blood and bronchoalveolar lavage (BAL) were evaluated at 1, 3, and 7 days post-injury. Levels of inflammatory cytokines in the lung were also profiled using protein macroarrays at day 3 post-injury which showed peak inflammation.
MSC transplantation increased survival and attenuated lung injuries in ALI mice, as evidenced by decreased injury scores on day 3 post-injury and reduced lung inflammation including increased MPO activity and protein levels of IL-1α, IL-1β, IL-6, TNF-α, and MIP-2 on day 3 and 7 post-injury. Inflammatory cytokine profiles in the lungs at day 3 post-injury were attenuated by MSC transplantation. MSCs also reduced the elevated lung water content at day 3 post-injury and bacterial counts in blood and BAL on day 7 post-injury.
Intratracheal transplantation of UCB-derived MSCs attenuates E. coli-induced ALI primarily by down-modulating the inflammatory process and enhancing bacterial clearance.
人脐血(UCB)衍生的间充质干细胞(MSCs)通过抗炎作用减轻新生鼠高氧肺损伤。我们假设,通过抑制炎症反应,气管内移植人 UCB 衍生的 MSCs 可减轻大肠杆菌(E. coli)诱导的急性肺损伤(ALI)。
将 8 周龄雄性 ICR 小鼠随机分为对照组或 ALI 组。通过气管内大肠杆菌滴注诱导 ALI。大肠杆菌滴注后 3 小时,随机给予 MSCs、成纤维细胞或磷酸盐缓冲盐水,分析损伤后 7 天的存活率。在损伤后 1、3 和 7 天,评估肺组织学,包括损伤评分、髓过氧化物酶(MPO)活性、白细胞介素(IL)-1α、IL-1β、IL-6、肿瘤坏死因子(TNF)-α和巨噬细胞炎症蛋白(MIP)-2 的蛋白水平,以及肺湿干重比和血液及支气管肺泡灌洗液(BAL)中的细菌计数。在损伤后 3 天,使用蛋白质宏阵列分析肺部炎症细胞因子水平,显示出炎症的高峰。
MSC 移植可增加 ALI 小鼠的存活率并减轻肺损伤,表现在损伤后 3 天的损伤评分降低,以及肺炎症减轻,包括 MPO 活性和 IL-1α、IL-1β、IL-6、TNF-α和 MIP-2 的蛋白水平在损伤后 3 天和 7 天升高。损伤后 3 天,MSC 移植可减轻肺部炎症细胞因子谱。MSC 还可降低损伤后 3 天的肺含水量升高,并降低损伤后 7 天的血液和 BAL 中的细菌计数。
气管内移植 UCB 衍生的 MSCs 主要通过下调炎症过程和增强细菌清除来减轻大肠杆菌诱导的 ALI。